These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11805225)

  • 21. Disruption of reelin signaling attenuates methamphetamine-induced hyperlocomotion.
    Matsuzaki H; Minabe Y; Nakamura K; Suzuki K; Iwata Y; Sekine Y; Tsuchiya KJ; Sugihara G; Suda S; Takei N; Nakahara D; Hashimoto K; Nairn AC; Mori N; Sato K
    Eur J Neurosci; 2007 Jun; 25(11):3376-84. PubMed ID: 17553006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of repeated treatment with tianeptine and fluoxetine on central dopamine D(2) /D(3) receptors.
    Dziedzicka-Wasylewska M; Rogoz Z; Skuza G; Dlaboga D; Maj J
    Behav Pharmacol; 2002 Mar; 13(2):127-38. PubMed ID: 11981225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of pargyline on brain N-tele-methylhistamine in portocaval-shunted rats: relation to amine neurotransmitters.
    Fogel WA; Tuomisto L; Sasiak K; Rokicki W; Rokicki M; MacDonald E; Maslinski C
    J Neurochem; 1994 Feb; 62(2):615-20. PubMed ID: 7905026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L-tetrahydropalmatine inhibits methamphetamine-induced locomotor activity via regulation of 5-HT neuronal activity and dopamine D3 receptor expression.
    Yun J
    Phytomedicine; 2014 Sep; 21(11):1287-91. PubMed ID: 25172791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum.
    Pillot C; Héron A; Schwartz JC; Arrang JM
    Eur J Neurosci; 2003 Jan; 17(2):307-14. PubMed ID: 12542667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S-[2-(4-imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist.
    Garbarg M; Arrang JM; Rouleau A; Ligneau X; Tuong MD; Schwartz JC; Ganellin CR
    J Pharmacol Exp Ther; 1992 Oct; 263(1):304-10. PubMed ID: 1383495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repeated intravenous cocaine administration: locomotor activity and dopamine D2/D3 receptors.
    Wallace DR; Mactutus CF; Booze RM
    Synapse; 1996 Jul; 23(3):152-63. PubMed ID: 8807743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences.
    Davidson C; Lee TH; Ellinwood EH
    Neurochem Int; 2005 Feb; 46(3):189-203. PubMed ID: 15670635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeated administration of a dopamine D1 receptor agonist reverses the increased proportions of striatal dopamine D1High and D2High receptors in methamphetamine-sensitized rats.
    Shuto T; Seeman P; Kuroiwa M; Nishi A
    Eur J Neurosci; 2008 May; 27(10):2551-7. PubMed ID: 18489579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of 5-HT receptors in the development and expression of methamphetamine-induced behavioral sensitization: 5-HT receptor channel and binding study.
    Yoo JH; Cho JH; Yu HS; Lee KW; Lee BH; Jeong SM; Nah SY; Kim HC; Lee SY; Jang CG
    J Neurochem; 2006 Nov; 99(3):976-88. PubMed ID: 16942594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine-independent psychostimulant activity of a delta-agonist.
    Ito S; Mori T; Sawaguchi T
    Behav Pharmacol; 2008 Mar; 19(2):113-9. PubMed ID: 18332675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of chronic cocaine administration on [3H]dopamine uptake in the nucleus accumbens, striatum and frontal cortex of rats.
    Masserano JM; Venable D; Wyatt RJ
    J Pharmacol Exp Ther; 1994 Jul; 270(1):133-41. PubMed ID: 8035309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.
    Siuciak JA; Fujiwara RA
    Psychopharmacology (Berl); 2004 Sep; 175(2):163-9. PubMed ID: 14985923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat.
    Pillot C; Ortiz J; Héron A; Ridray S; Schwartz JC; Arrang JM
    J Neurosci; 2002 Aug; 22(16):7272-80. PubMed ID: 12177222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice.
    Maeda T; Kiguchi N; Fukazawa Y; Yamamoto A; Ozaki M; Kishioka S
    Neuropsychopharmacology; 2007 May; 32(5):1133-40. PubMed ID: 17019405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of dopamine in the locomotor stimulant effects and tolerance to these effects of caffeine.
    Powell KR; Iuvone PM; Holtzman SG
    Pharmacol Biochem Behav; 2001; 69(1-2):59-70. PubMed ID: 11420069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ciproxifan, a histamine H₃-receptor antagonist / inverse agonist, modulates methamphetamine-induced sensitization in mice.
    Motawaj M; Arrang JM
    Eur J Neurosci; 2011 Apr; 33(7):1197-204. PubMed ID: 21366724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
    Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
    J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.